Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus

Archive ouverte

Tan, Boun Kim | Chalouni, Mathieu | Ceron, Dominique Salmon | Cinaud, Alexandre | Esterle, Laure | Loko, Marc Arthur | Katlama, Christine | Poizot-Martin, Isabelle | Neau, Didier | Chas, Julie | Morlat, Philippe | Rosenthal, Eric | Lacombe, Karine | Naqvi, Alissa | Barange, Karl | Bouchaud, Olivier | Gervais, Anne | Lascoux-Combe, Caroline | Garipuy, Daniel | Alric, Laurent | Goujard, Cécile | Miailhes, Patrick | Aumaitre, Hugues | Duvivier, Claudine | Simon, Anne | Lopez-Zaragoza, Jose-Luis | Zucman, David | Raffi, François | Lazaro, Estibaliz | Rey, David | Piroth, Lionel | Boué, François | Gilbert, Camille | Bani-Sadr, Firouzé | Dabis, François | Sogni, Philippe | Wittkop, Linda | Boccara, Franck

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Abstract Background An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying factors associated with atherosclerotic CVD (ASCVD) events. Methods HIV-HCV coinfected patients were enrolled in the Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) CO13 HEPAVIH nationwide cohort. Primary outcome was total ASCVD events. Secondary outcomes were coronary and/or cerebral ASCVD events, and peripheral artery disease (PAD) ASCVD events. Incidences were estimated using the Aalen-Johansen method. Factors associated with ASCVD were identified using cause-specific Cox proportional hazards models. Results At baseline, median age of the study population (N = 1213) was 45.4 (interquartile range [IQR] 42.1−49.0) years and 70.3% were men. After a median follow-up of 5.1 (IQR 3.9−7.0) years, the incidence was 6.98 (95% confidence interval [CI], 5.19−9.38) per 1000 person-years for total ASCVD events, 4.01 (2.78−6.00) for coronary and/or cerebral events, and 3.17 (2.05−4.92) for PAD ASCVD events. Aging (hazard ratio [HR] 1.06; 95% CI, 1.01−1.12), prior CVD (HR 8.48; 95% CI, 3.14−22.91), high total cholesterol (HR 1.43; 95% CI, 1.11−1.83), high-density lipoprotein cholesterol (HR 0.22; 95% CI, 0.08−0.63), statin use (HR 3.31; 95% CI, 1.31−8.38), and high alcohol intake (HR 3.18; 95% CI, 1.35−7.52) were independently associated with total ASCVD events, whereas undetectable baseline viral load (HR 0.41, 95% CI, 0.18−0.96) was associated with coronary and/or cerebral events. Conclusions HIV-HCV coinfected patients experienced a high incidence of ASCVD events. Some traditional cardiovascular risk factors were the main determinants of ASCVD. Controlling cholesterol abnormalities and maintaining undetectable HIV RNA are essential to control cardiovascular risk.

Consulter en ligne

Suggestions

Du même auteur

Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus

Archive ouverte | Tan, Boun, Kim | CCSD

International audience. Background: An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying fact...

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

Archive ouverte | Billa, Oumar | CCSD

International audience. Compared to the general population, HIV-infected patients are at higher risk of developing non-AIDS-defining cancers. Chronic HCV infection has also been associated with a higher risk than th...

Efficacy and Safety of Direct-Acting Antiviral Regimens in HIV/HCV-co-infected Patients \textendash French ANRS CO13 HEPAVIH Cohort

Archive ouverte | Piroth, Lionel | CCSD

International audience

Chargement des enrichissements...